Nuevos fármacos en oncologíaefectos secundarios cutáneos y su manejo
- Hernández, A. Cabrera
- Zubiaur, A. Gómez
- Koch, C. Guirado
- Expósito, F. Navarro
- Bandini, M.
- Duarte, A. García
- Surmann, I. Hernández
- Montalvo, S. Medina
- Marugán, L. Trasobares
ISSN: 0304-5412
Year of publication: 2017
Issue Title: Enfermedades oncológicas (I) Cáncer de pulmón. Cáncer de cabeza y cuello
Series: 12
Issue: 31
Pages: 1874-1882
Type: Article
More publications in: Medicine: Programa de Formación Médica Continuada Acreditado
Sustainable development goals
Abstract
Abstract Introduction The new anti cancer drugs have been a major therapeutic advance in recent years, but have resulted in previously unknown adverse skin effects. The aim of this protocol is to review and report the main adverse effects of the new anti cancer drugs, and to offer some basic guidelines for their treatment. Clinical picture Skin symptoms after use of these new therapies vary greatly, but there are certain adverse effects that are characteristic of a specific therapeutic group. Treatment Treatment should be individual based on the type of skin condition, intensity of symptoms, potential gravity of skin symptoms, and the general condition of the patient. Prognosis. Although symptoms can impair patients’ quality of life to a significant extent, they are rarely life-threatening. Conclusion Given the growing use of the new targeted molecular therapies, it is important to be familiar with the skin symptoms that these can cause, to know their basic initial management, and how they evolve over subsequent cycles of anti cancer treatment.
Bibliographic References
- Guhl G, González de Arriba A, Daudén E. Efectos cutáneos de los inhibidores del receptor del factor de crecimiento epidérmico. Actas Dermosifiliogr. 2006; 97:296-310.
- Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-33.
- Ara M, Pastushenko E. Fármacos antiangiogénicos y piel: efectos cutáneos adversos de sorafenib, sunitinib y bevacizumab. Actas Dermosifilio gr. 2014;105:900-12.
- Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S. Cutaneous adverse events (AEs) of antiprogrammed cell death (PD)-1 thera-phy in patients with metastatic melanoma: A single institution cohort. J Am Acad Dermatol. 2016;74:455-61.
- Postow MA. Managing immune checkpoint blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;35:2092-9.
- Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Derma-tologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254-63.